600645.SS
600645.SS
CNE000000545
VCANBIO CELL & GENE ENG CORP LT
Loading chart...

Company Profile

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells and dental stem cells. The company also provides prenatal genetic testing for pregnancy, children and adults, disease inheritance, and disease susceptibility; and in vitro diagnostic raw materials such as monoclonal antibodies and polyclonal antibody products, and the research, development, production and sales of Class I, Class II and Class III in vitro diagnostic reagents and medical devices. In addition, it is involved in the research, development, production, and sales of biological genes, proteins, antibodies, and pharmaceutical intermediates. The company was founded in 1992 and is based in Tianjin, the People's Republic of China.

Related stocks

1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
9887.HK
9887.HK • China
LEADS BIOLABS-B
45.56 HKD
1.15B USD 1Y -37.5%
9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
603229.SS
603229.SS • China
ZHEJIANG AUSUN PHARMACEUTICAL C
8.19 CNY
1.02B USD 1Y -19.8%
300049.SZ
300049.SZ • China
FRMS CO., LTD
40.49 CNY
1.6B USD 1Y -44.3%
688382.SS
688382.SS • China
INVENTISBIO CO LTD
17.26 CNY
1.5B USD 1Y -42.5%
002287.SZ
002287.SZ • China
CHEEZHENGTTM
19.56 CNY
1.67B USD 1Y -24.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
40.1% p.a.
Max Drawdown (5Y)
-53.3%
Sharpe Ratio (5Y)
-0.17
Beta Factor
-0.10
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 73.5 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -60.6% in the extended horizon.
ende